Amgen (AMGN) Stock Price, News & Analysis

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.

19 analysts have issued 12-month target prices for Amgen's stock. Their AMGN share price targets range from $200.00 to $350.00. On average, they predict the company's stock price to reach $295.30 in the next year. This suggests a possible upside of 0.2% from the stock's current price.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

Amgen's stock was trading at $288.02 at the beginning of 2024. Since then, AMGN stock has increased by 2.4% and is now trading at $294.85.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our AMGN earnings forecast.

Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings data on Tuesday, February, 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The medical research company earned $8.20 billion during the quarter, compared to analysts' expectations of $8.13 billion. Amgen had a net margin of 23.83% and a trailing twelve-month return on equity of 152.15%. The firm's quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.09 EPS.
Read the conference call transcript.

Amgen announced a quarterly dividend on Tuesday, December 12th. Shareholders of record on Friday, February 16th will be paid a dividend of $2.25 per share on Thursday, March 7th. This represents a $9.00 annualized dividend and a dividend yield of 3.05%. The ex-dividend date of this dividend is Thursday, February 15th. This is a positive change from the stock's previous quarterly dividend of $2.13.
Read our dividend analysis for AMGN.

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 2.70%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 68.21%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 40.26% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), FT Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD).

Amgen updated its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of 18.900-20.300 for the period, compared to the consensus estimate of 20.000. The company issued revenue guidance of $32.4 billion-$33.8 billion, compared to the consensus revenue estimate of $32.7 billion.

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Amgen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Charles Schwab Investment Management Inc. (1.94%), California Public Employees Retirement System (0.51%), Dimensional Fund Advisors LP (0.46%), LSV Asset Management (0.34%), Nordea Investment Management AB (0.34%) and Boston Partners (0.33%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.